Jul 2026· Journal of Cardiothoracic Surgery· 0 citations
Abstract
Atherosclerosis is a leading global cause of disability and mortality, with a rising trend of early onset across populations. Its pathogenesis is multifactorial, encompassing multiple interconnected pathways including dyslipidemia, inflammation, and immune dysregulation. Current therapeutic strategies targeting lipoproteins are insufficient to address disease progression, and there remains an urgent unmet clinical need to further elucidate its pathogenic mechanisms, refine diagnostic approaches, and identify novel therapeutic targets. In recent years, the vigorous development of omics technology has provided help for in-depth investigation of the pathogenesis of diseases and search for new diagnosis and treatment targets. The application of multi-omics analysis has elevated atherosclerotic research to a new tier, yielding high-quality findings that further unravel atherogenic molecular mechanisms. These findings provide critical theoretical and translational groundwork for developing novel diagnostics, targeted therapies, and robust early risk stratification tools. In this review, we summarize integrated multi-omics applications in atherosclerosis, and outline novel perspectives for prospective therapeutic strategies.
Recent findings from large population-based studies are described to illustrate the value of proteomics in cardiology for improved risk prediction, diagnosis and patient stratification; better understanding of disease aetiology and pathophysiology; and identification of repurposing and novel therapeutic targets.
Recent technological advances and applications of multi-omics in kidney diseases are critically reviewed, with particular attention to biomarker discovery and clinical translation, and the challenges and future directions of multi-omics integration and its application in precision medicine are discussed.
This narrative review critically evaluates how multi-omics integration strategies can improve precision risk stratification throughout the T1D disease continuum by integrating complementary molecular information from genomics, transcriptomics, proteomics, proteomics, metabolomics, epigenomics, and the microbiome.
Zi-Yi Chen, Wen-Tao Liu, Zheng Guo et al.· Frontiers in Immunology· 0 citations
This review elucidates the complex pathophysiology, epidemiological dynamics, and genetic architectures defining dyslipidaemia, delineating primary hereditary molecular defects from secondary acquired etiologies and discusses persistent barriers to patient adherence and the transformative potential of precision medicin...
A. Qadir, R. Omer, H. Barzani et al.· Russian journal of bioorgani...· 0 citations
This paper analyzes the challenges faced by multi-omics biomarkers during clinical translation, including technical barriers, cost-effectiveness, and standardization, and critically evaluates the nascent integration of spatialomics and liquid biopsy technologies within the “multi-omics + AI” framework.
De-Sheng Wu, Li-Hung Chang, Juan Chai· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.